Intangible assets (Tables)

12 Months Ended

Nov. 30, 2023



	Commercialization rights – Trogarzo ® North American Territory		Commercialization rights – Trogarzo ® European Territory		Commercialization rights – EGRIFTA SV ®		Oncology platform		Total


Cost

Balance as at November 30, 2021		$ 11,972		$ 7,612		$ 14,041		$ 3,488		$ 37,113

Additions		2,832		-		-		-		2,832


Balance as at November 30, 2022		$ 14,804		$ 7,612		$ 14,041		$ 3,488		$ 39,945

Disposal		-		(7,612)		-		-		(7,612)

Balance as at November 30, 2023		$ 14,804		$ -		$ 14,041		$ 3,488		$ 32,333


Accumulated amortization

Balance as at November 30, 2021		$ 3,267		$ 999		$ 11,459		-		$ 15,725

Amortization		1,087		6,613		1,511		-		9,211


Balance as at November 30, 2022		$ 4,354		$ 7,612		$ 12,970		-		$ 24,936

Disposal		$ -		(7,612)		-		-		(7,612)

Amortization		$ 1,442		$ -		$ 1,071		-		$ 2,513


Balance as at November 30, 2023		$ 5,796		$ -		$ 14,041		-		$ 19,837


Net carrying amounts

November 30, 2023		$ 9,008		$ -		$ -		$ 3,488		$ 12,496

November 30, 2022		$ 10,450		$ -		$ 1,071		$ 3,488		$ 15,009

As further consideration under the TaiMed Agreement, the Company shall make the following

one-time

payments upon the first occurrence of the following commercial events:


Commercial milestone	Commercial milestone payment

(i) Upon first achieving annual net sales of $200,000		$10,000

(ii) Upon first achieving annual net sales of $500,000		$40,000

(iii) Upon first achieving annual net sales of $1,000,000		$100,000